ArticleFrontiers in immunology2026

Correction: Efficacy and safety of anlotinib combined with PD-1/PD-L1 inhibitors in malignant solid tumors: a meta-analysis and network meta-analysis.

Chen Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.